Laryngeal squamous cell carcinoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:23:30 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Laryngeal squamous cell carcinoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Evaluation of Lymphocyte-Sparing Radiotherapy and All-Trans Retinoic Acid in Lateralized Oropharyngeal, Laryngeal, and Hypopharyngeal Squamous Cell Carcinoma https://clinicaltrials.eu/trial/evaluation-of-lymphocyte-sparing-radiotherapy-and-all-trans-retinoic-acid-in-lateralized-oropharyngeal-laryngeal-and-hypopharyngeal-squamous-cell-carcinoma/ Thu, 07 May 2026 05:47:01 +0000 https://clinicaltrials.eu/trial/evaluation-of-lymphocyte-sparing-radiotherapy-and-all-trans-retinoic-acid-in-lateralized-oropharyngeal-laryngeal-and-hypopharyngeal-squamous-cell-carcinoma/ This clinical trial is focused on studying treatments for a type of cancer known as squamous cell carcinoma that affects the head and neck area, specifically the oropharynx, larynx, and hypopharynx. The study will explore the effects of a medication called all-trans retinoic acid (ATRA), also known by its brand name Vesanoid, in combination with different approaches to radiotherapy, which is a treatment that uses high-energy rays to target and kill cancer cells.

The purpose of the study is to assess how effective ATRA and tailored radiotherapy are in treating patients with localized squamous cell carcinoma of the head and neck. Participants in the study will receive either standard or reduced-target volume radiotherapy, with or without ATRA. The study will also involve the use of other medications, including cetuximab and cisplatin, which are commonly used in cancer treatment. Cetuximab is a protein-based medication, while cisplatin is a chemical compound used to stop the growth of cancer cells.

Throughout the study, participants will receive treatments over a period of time and will be monitored for their response to the therapy. The study aims to understand the impact of these treatments on the survival and quality of life of patients, as well as any potential side effects. The ultimate goal is to improve treatment strategies for head and neck cancer, providing better outcomes for patients.

]]> Study on Pembrolizumab and Drug Combination for Patients with Recurrent Head and Neck Cancer https://clinicaltrials.eu/trial/study-on-pembrolizumab-and-drug-combination-for-patients-with-recurrent-head-and-neck-cancer/ Wed, 29 Apr 2026 15:05:01 +0000 https://clinicaltrials.eu/trial/study-on-pembrolizumab-and-drug-combination-for-patients-with-recurrent-head-and-neck-cancer/ This clinical trial is focused on studying a type of cancer called locoregionally recurrent head and neck squamous cell carcinoma (HNSCC). This is a condition where cancer returns in the head and neck area after initial treatment. The study will explore the effectiveness of a treatment plan that includes a combination of therapies. The main treatment being tested is pembrolizumab, which is a type of immunotherapy that helps the immune system fight cancer. The study will compare this treatment to the standard therapy, which may include pembrolizumab with or without chemotherapy.

The trial will involve several medications, including fluorouracil, carboplatin, and cisplatin, which are types of chemotherapy drugs. These medications are given to help stop the growth of cancer cells. The purpose of the study is to see if the new treatment plan can improve the overall survival of patients with this type of cancer. Participants in the study will receive these treatments over a period of time, and their health will be monitored to see how well the treatment works.

The study will follow a specific course where participants will receive the treatments through intravenous infusion, which means the medication is given directly into a vein. The trial aims to find out if the new treatment plan can help patients live longer and control the cancer better than the current standard treatments. The study will also look at other factors, such as how the treatment affects the quality of life and any side effects that may occur. The ultimate goal is to find a more effective way to treat this type of cancer and improve the lives of those affected by it.

]]> Study of low-dose radiation therapy combined with paclitaxel and carboplatin in patients with advanced throat and larynx cancer https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-low-dose-radiochemotherapy-with-carboplatin-and-paclitaxel-for-patients-with-advanced-throat-and-larynx-cancer/ Wed, 29 Apr 2026 15:02:24 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-low-dose-radiochemotherapy-with-carboplatin-and-paclitaxel-for-patients-with-advanced-throat-and-larynx-cancer/ This clinical trial focuses on patients with advanced throat and larynx cancer. The study evaluates a treatment approach called induction radiochemotherapy that uses low doses of ionizing radiation combined with chemotherapy medications. The chemotherapy drugs used in this study are paclitaxel and carboplatin, which are given through an intravenous injection directly into the bloodstream.

The purpose of this research is to determine how effective and well-tolerated this combined treatment approach is for patients with advanced throat and larynx cancer. The treatment involves receiving both chemotherapy medications along with low-dose radiation therapy. During the study, patients will receive treatment over a period of up to 37 days.

The study will monitor how patients respond to the treatment by examining the cancer’s response, checking for any spread of the disease, and tracking overall patient survival. The research will also look at how low doses of radiation affect the body at both molecular and biochemical levels. Throughout the treatment period, doctors will carefully watch for and record any side effects that patients may experience.

]]> Study on the Safety and Effectiveness of Afatinib for Fanconi Anemia Patients with Advanced Squamous Cell Carcinoma in the Oral Cavity, Oropharynx, Hypopharynx, or Larynx https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-afatinib-for-fanconi-anemia-patients-with-advanced-squamous-cell-carcinoma-in-the-oral-cavity-oropharynx-hypopharynx-or-larynx/ Wed, 29 Apr 2026 15:01:07 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-afatinib-for-fanconi-anemia-patients-with-advanced-squamous-cell-carcinoma-in-the-oral-cavity-oropharynx-hypopharynx-or-larynx/ This clinical trial is focused on studying the effects of a medication called Afatinib in patients with a rare genetic disorder known as Fanconi anemia. This disorder can lead to a type of cancer called squamous cell carcinoma, which affects areas such as the mouth, throat, and voice box. The study aims to understand how safe and effective Afatinib is when used to treat these cancers, especially when they cannot be surgically removed or have spread to other parts of the body.

The treatment involves taking Afatinib in the form of film-coated tablets, which are taken orally. The study will compare the effects of different doses of Afatinib to see how well it works in controlling the cancer and improving the quality of life for patients. Participants will be monitored for any side effects and how their cancer responds to the treatment over a period of time.

The purpose of this study is to gather information on the effectiveness of Afatinib in treating cancers associated with Fanconi anemia. The study will also look at how long the treatment effects last, the overall survival of patients, and any changes in their health-related quality of life. This information will help in understanding the potential benefits and risks of using Afatinib for this specific group of patients.

]]> Study of Pembrolizumab with Lenvatinib after Chemoradiation Treatment in Patients with Locally Advanced Head and Neck Cancer who are PD-L1 Positive https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-lenvatinib-for-patients-with-advanced-head-and-neck-cancer-after-chemoradiation/ Wed, 29 Apr 2026 14:59:19 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-lenvatinib-for-patients-with-advanced-head-and-neck-cancer-after-chemoradiation/ This study focuses on patients with locally advanced head and neck squamous cell carcinoma, a type of cancer that develops in the cells lining the mouth, throat, or surrounding areas. The research examines two medications: pembrolizumab and lenvatinib. These medications will be given to patients after they have completed their initial cancer treatment with chemotherapy and radiation therapy.

The purpose of this research is to determine if using both pembrolizumab and lenvatinib together works better than using pembrolizumab alone in preventing cancer from returning. Pembrolizumab is given through an intravenous infusion into a vein, while lenvatinib is taken as oral capsules. The treatment period may last up to 47 weeks.

The study will include patients whose cancer cells have a specific characteristic called PD-L1, which is a protein found on some cancer cells. Patients will receive regular medical check-ups throughout the study period to monitor their health and evaluate how well the treatment is working. The medications being studied are designed to help the body’s immune system fight cancer cells.

]]> Study on Preserving the Voice Box in Patients with Advanced Laryngeal or Hypopharyngeal Cancer Using Cisplatin, Fluorouracil, and Docetaxel Therapy https://clinicaltrials.eu/trial/study-on-preserving-the-voice-box-in-patients-with-advanced-laryngeal-or-hypopharyngeal-cancer-using-cisplatin-fluorouracil-and-docetaxel-therapy/ Wed, 29 Apr 2026 14:27:17 +0000 https://clinicaltrials.eu/trial/study-on-preserving-the-voice-box-in-patients-with-advanced-laryngeal-or-hypopharyngeal-cancer-using-cisplatin-fluorouracil-and-docetaxel-therapy/ This clinical trial is focused on studying treatments for squamous cell carcinoma of the larynx or hypopharynx, which are types of throat cancer that have advanced locally. The study aims to compare two different treatment approaches to see which one is more effective in preserving the function of the larynx, which is the voice box, and the pharyngoesophageal area, which is part of the throat and esophagus. The treatments being tested include a combination of chemotherapy drugs: cisplatin, 5-fluorouracil, and docetaxel. These drugs are used to kill cancer cells and are given through an infusion, which means they are delivered directly into the bloodstream through a vein.

Participants in the study will receive either the combination of these chemotherapy drugs followed by radiotherapy or a treatment where cisplatin is given at the same time as radiotherapy. Radiotherapy is a treatment that uses high-energy rays to target and destroy cancer cells. The purpose of the study is to determine which treatment method is better at helping patients survive without losing the function of their larynx or needing major surgery like a total laryngectomy, which is the removal of the larynx.

The study will take place over several months, and participants will be monitored for their response to the treatment, any side effects they experience, and their overall health. The goal is to find the most effective way to treat this type of cancer while preserving the patient’s ability to speak and swallow normally. The study will also look at the overall survival rates and the quality of life of the participants during and after the treatment.

]]>